---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-024500"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T00:38:28.474174+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Galectin Therapeutics Q1 net loss widens to $11.5M; NAVIGATE trial fully enrolled with 357 patients

## Summary
- Net loss of $11.5M ($0.19/shr) vs $9.9M loss in Q1 2022, driven by higher R&D costs.
- R&D expenses rose to $8.8M from $8.1M, primarily for the NAVIGATE trial.
- Cash and equivalents $17.8M; additional $40M available under chairman's line of credit.
- NAVIGATE Phase 2b/3 trial for NASH cirrhosis esophageal varices enrolled 357 patients; interim results expected Q4 2024.
- Company evaluating potential Phase 2 trial of belapectin + Keytruda in advanced head and neck cancers.

## SEC filing metadata
- accession: 0001140361-23-024500
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036123024500/0001140361-23-024500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036123024500/brhc20052846_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-024500
- JSON: https://secwatch.observer/filing/0001140361-23-024500.json
- Plain text: https://secwatch.observer/filing/0001140361-23-024500.txt

## Key facts
- Earnings Releases
  GALECTIN THERAPEUTICS INC reported three months ended March 31, 2023 results: net income net loss applicable to common stockholders of $11.5 million, or ($0.19) per share, EPS ($0.19) per share.
  - Period: three months ended March 31, 2023
  - Net income: net loss applicable to common stockholders of $11.5 million, or ($0.19) per share
  - EPS: ($0.19) per share
  - Result: reported results
  source text: Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1133416/000114036123024500/0001140361-23-024500-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.